Anti-Arrhythmic Drug Therapy
Phase 3Small molecule
Anti-Arrhythmic Drug Therapy is one of 48 small molecule programs targeting Paroxysmal atrial fibrillation. It is currently in Phase 3.
2
Indications
3
Total Trials
0
Active Trials
47
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
376 competitors in Atrial Fibrillation
#DrugCompanyPhaseTrials
1Anti-Arrhythmic Drug Therapy
UUniversity of British Columbia
Phase 3
Calquence
AstraZenecaPreclinical
Calan
VVal Adams
Preclinical
Ondexxya
UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
Preclinical
Brukinsa
BBeOne Medicines
Preclinical
Romazicon
CConrado Roberto Hoffmann Filho
Preclinical
Versed
CConrado Roberto Hoffmann Filho
Preclinical
Low-Molecular-Weight Heparin
Daiichi SankyoPreclinical
Statin
Bristol-Myers SquibbPreclinical
Liquamar
OOrganon and Co
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- UUniversity of British Columbia